PF-06895751

PF-06895751 (also known as RN927) is an antibody-drug conjugate (ADC) developed by Pfizer for the treatment of advanced solid tumors. It consists of a humanized monoclonal antibody targeting Programmed Death-Ligand 1 (PD-L1) conjugated to the potent microtubule-disrupting agent monomethyl auristatin E (MMAE) via a protease-cleavable valine-citrulline linker. The ADC is designed to bind to PD-L1-expressing tumor cells, undergo internalization, and release the cytotoxic MMAE payload intracellularly, leading to cell cycle arrest and apoptosis. Beyond its direct cytotoxic effects, PF-06895751 may also function as a checkpoint inhibitor by blocking the PD-1/PD-L1 interaction, potentially enhancing the anti-tumor immune response within the tumor microenvironment.

Other names

anti-PD-L1-vcMMAEanti-PD-L-1-vcMMAEanti-PD-L 1-vcMMAEPD-L1 ADCPD-L-1 ADCPD-L 1 ADC